YHB Investment Advisors Inc. Sells 1,700 Shares of Celgene Co. (NASDAQ:CELG)

YHB Investment Advisors Inc. cut its holdings in Celgene Co. (NASDAQ:CELG) by 3.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,877 shares of the biopharmaceutical company’s stock after selling 1,700 shares during the period. YHB Investment Advisors Inc.’s holdings in Celgene were worth $4,148,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the stock. Archford Capital Strategies LLC lifted its position in Celgene by 277.8% during the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 200 shares during the last quarter. Investors Research Corp acquired a new position in Celgene during the 1st quarter worth $28,000. Liberty Wealth Management LLC acquired a new position in Celgene during the 4th quarter worth $29,000. Weaver Consulting Group acquired a new position in Celgene during the 1st quarter worth $29,000. Finally, Alera Investment Advisors LLC lifted its position in Celgene by 109.9% during the 1st quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 167 shares during the last quarter. Hedge funds and other institutional investors own 74.84% of the company’s stock.

A number of research analysts have weighed in on CELG shares. Zacks Investment Research lowered shares of Phoenix New Media from a “hold” rating to a “sell” rating in a research report on Tuesday, July 23rd. BidaskClub raised shares of Xilinx from a “hold” rating to a “buy” rating in a research report on Wednesday, July 24th. Cowen boosted their target price on shares of AerCap from $56.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday. Mizuho set a $148.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, July 3rd. Finally, Barclays set a $24.00 target price on shares of Orion Engineered Carbons and gave the stock a “hold” rating in a research report on Friday, May 3rd. Two analysts have rated the stock with a sell rating, sixteen have issued a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $94.81.

Shares of CELG traded down $0.03 during trading hours on Wednesday, reaching $92.58. 1,479,665 shares of the company traded hands, compared to its average volume of 3,638,123. The firm has a fifty day moving average of $93.61. The firm has a market cap of $65.42 billion, a PE ratio of 12.17, a P/E/G ratio of 0.44 and a beta of 1.45. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $98.97.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.17. The business had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.22 billion. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The firm’s revenue for the quarter was up 15.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.16 earnings per share. Sell-side analysts predict that Celgene Co. will post 9.85 EPS for the current fiscal year.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.